Data from Greater Bay Area’s 88 million residents to help improve healthcare policy: GSK

British pharmaceutical company GSK is turning to patient data gathered from the 88 million residents of the Greater Bay Area’s 11 cities to speed up drug development in vaccines and cancer care, as officials push for closer cross-border medical cooperation.GSK Hong Kong and Macau general manager Nicholas Teo said patient data was very important because it could form “supplementary evidence” to support regulatory filings and potential label expansions, and also help to “discover benefits other than the medication itself”.vaccines were one example, Teo said last week. While their effectiveness against target diseases such as flu, shingles and respiratory syncytial virus was well established, he said researchers were increasingly studying potential benefits relating to cardiovascular health and neurological outcomes, which might help generate additional evidence and insights for future healthcare decision-making.